Ibio (IBIO) AI Stock Analysis

• Market Cap: $24.06M
• Dividend Yield: N/A
• Average Volume (3M): 5.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: 185.71%
• EPS Growth: 79.03%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 22,487,309
• 10 Day Avg. Volume: 796,559
• 30 Day Avg. Volume: 5,935,045
• PEG Ratio: <0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 20.03
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: -0.10
• Enterprise Value/Revenue: -4.83
• Enterprise Value/Gross Profit: -11.45
• Enterprise Value/Ebitda: 0.13
• 1Y Price Target: $3.90
• Price Target Upside: 275.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.27
• Revenue Forecast (FY): $300.00K

• Rating: 41 Neutral
• Price Target: $1.00 ▼(-3.85% Downside)

Ibio's overall stock score is primarily impacted by its poor financial performance and unattractive valuation. The technical analysis suggests a neutral market sentiment, but the lack of profitability and cash flow issues are significant concerns. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Innovative Product Development

The promising preclinical data for IBIO-610 highlights iBio's potential to develop innovative therapies, strengthening its pipeline and market position in cardiometabolic and obesity diseases.

Revenue Growth

Exceeding revenue expectations indicates effective business strategies and market demand, supporting long-term growth prospects and financial stability.

Low Debt Levels

A low debt-to-equity ratio suggests manageable leverage, providing financial flexibility and reducing risk of financial distress, supporting long-term sustainability.

Negative Factors

Negative Profit Margins

Consistently negative profit margins indicate operational inefficiencies and challenges in achieving profitability, posing risks to long-term financial health.

Cash Flow Challenges

Negative cash flow indicates insufficient cash generation from operations, impacting the company's ability to fund growth and meet financial obligations.

Operational Inefficiencies

Deeply negative EBIT and EBITDA margins suggest significant operational inefficiencies, hindering the company's ability to improve profitability and compete effectively.

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

How the Company Makes Money

Ibio generates revenue through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with other biotech firms and academic institutions to co-develop its products, sharing in the financial benefits of successful outcomes. Additionally, Ibio may receive upfront payments, milestone payments, and royalties from its partners based on the sales of products developed using its technology. The revenue model is further supported by grants and contracts, particularly for vaccine development and other projects that align with public health initiatives.

Ibio Financial Statement Overview

Summary

Ibio faces significant financial challenges, with persistent losses and negative cash flows. Despite a low debt-to-equity ratio, the company's inability to generate profits and positive cash flow raises concerns about its long-term sustainability.

Income Statement

Ibio's income statement reveals significant challenges with profitability. Despite a slight revenue growth of 6.67% in the latest year, the company has consistently reported negative net profit margins, with the most recent at -45.94%. The EBIT and EBITDA margins are also deeply negative, indicating operational inefficiencies. The gross profit margin remains positive, but the overall financial health is hindered by substantial losses.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.24, suggesting manageable leverage levels. However, the return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio indicates a moderate level of equity financing, but the persistent losses pose a risk to financial stability.

Cash Flow

Cash flow analysis highlights ongoing cash flow challenges. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its losses. Free cash flow growth is negative, and the free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported losses, but overall cash management remains a concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	500.00K	400.00K	225.00K	0.00	1.88M	2.37M
Gross Profit	211.00K	400.00K	225.00K	0.00	-1.91M	909.00K
EBITDA	-18.78M	-17.04M	-14.02M	-27.85M	-25.72M	-28.55M
Net Income	-20.11M	-18.38M	-24.91M	-65.01M	-50.39M	-23.21M
Balance Sheet
Total Assets	64.16M	23.18M	28.73M	41.21M	99.41M	146.97M
Cash, Cash Equivalents and Short-Term Investments	49.57M	8.58M	14.21M	7.33M	33.52M	96.97M
Total Debt	3.29M	3.51M	4.46M	17.07M	25.77M	32.72M
Total Liabilities	8.12M	8.30M	7.41M	25.83M	35.92M	38.40M
Stockholders Equity	56.04M	14.88M	21.32M	15.38M	63.48M	108.58M
Cash Flow
Free Cash Flow	-17.30M	-15.32M	-18.76M	-36.17M	-45.13M	-35.23M
Operating Cash Flow	-17.25M	-15.30M	-18.55M	-30.44M	-37.80M	-30.06M
Investing Cash Flow	-21.46M	742.00K	906.00K	7.01M	-5.13M	-26.48M
Financing Cash Flow	55.80M	8.93M	24.49M	2.30M	-5.80M	78.83M

Ibio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.04
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Negative. The current price of 1.04 is below the 20-day moving average (MA) of 1.18, below the 50-day MA of 1.10, and below the 200-day MA of 1.53, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 37.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PULM	53 Neutral	$16.40M	―	-79.47%	―	-99.97%	35.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	41 Neutral	$24.06M	―	-54.50%	―	185.71%	79.03%
FBLG	38 Underperform	$16.83M	-0.68	-1292.87%	―	―	18.47%
NERV	34 Underperform	$25.67M	2.47	―	―	―	-323.61%
CMMB	33 Underperform	$13.81M	-1.09	-73.63%	―	―	53.19%

Ibio Corporate Events

iBio Confirms Directors and Auditor at Annual Meeting

On November 20, 2025, iBio, Inc. held its Annual Meeting of Stockholders where four proposals were voted on. The election of two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, was confirmed for a three-year term. Stockholders ratified Grassi & Co. as the independent auditor for the fiscal year ending June 30, 2026. Additionally, stockholders approved executive compensation on an advisory basis and decided on a one-year frequency for future advisory votes on executive compensation, aligning with the Board’s recommendation.

The most recent analyst rating on (IBIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio, Inc. Reports Q3 2025 Financial Results

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence for developing precision antibodies targeting cardiometabolic and obesity-related conditions. The company focuses on creating innovative biologics using its AI Drug Discovery Platform to address unmet medical needs.

iBio Regains Nasdaq Compliance with Bid Price Rule

On November 4, 2025, iBio, Inc. announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. This follows a previous notification on July 29, 2025, indicating non-compliance due to the company’s stock price falling below the required threshold between June 13, 2025, and July 28, 2025. The issue is now resolved, closing the matter.

The most recent analyst rating on (IBIO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Unveils Promising Preclinical Data for IBIO-610

On October 30, 2025, iBio, Inc. announced new preclinical data from its study on IBIO-610, an Activin E antibody candidate, showing an extended half-life of 33.2 days in obese non-human primates. This data, to be presented at ObesityWeek 2025, predicts a human half-life of up to 100 days, potentially allowing for twice-yearly dosing, which could significantly enhance patient experience and position IBIO-610 as a leading therapy for obesity and cardiometabolic diseases.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

Ibio Inc’s Future at Risk: Reliance on Third-Party Licenses for Key Product Candidates

Ibio Inc faces significant business risks due to its reliance on intellectual property licensed from third parties, particularly concerning its advanced product candidates, IBIO-600 and IBIO-610. These dependencies are tied to exclusive agreements with AstralBio, which grant Ibio Inc the rights to develop and commercialize these candidates. The termination of these licenses could lead to the loss of critical rights, adversely affecting the company’s ability to bring these products to market. Additionally, disputes over intellectual property or failure by licensors to enforce patents could further jeopardize Ibio Inc’s operations and financial health.

iBio, Inc. Reports Transformative Fiscal Year 2025

iBio, Inc. is a biotechnology company that leverages artificial intelligence and advanced computational biology to develop precision antibody therapies for cardiometabolic diseases, obesity, cancer, and other hard-to-treat conditions.

iBio Announces $50 Million Public Offering Agreement

On August 19, 2025, iBio, Inc. announced an underwriting agreement with Leerink Partners LLC for a public offering involving pre-funded warrants and Series G and H warrants to purchase shares of common stock. The offering, expected to raise approximately $50 million, aims to advance iBio’s preclinical cardiometabolic programs and other pipeline assets. The company has agreed to certain restrictions on stock issuance and sale for 90 days following the offering’s pricing. The offering’s completion is subject to customary closing conditions, with the closing expected around August 22, 2025.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.